GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Gemcitabine injection (GEMZAR)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

Gemzar

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Gemcitabine: initial CKD guidance does not cancel a toxicity stop rule

eviQ supplies an initial indexed-eGFR approach for advanced pancreatic cancer. GEMZAR separately requires stopping for HUS or severe renal toxicity. These address different clinical states rather than permission to continue despite new injury.

Before applying: Establish baseline stability versus new drug-associated injury, indication and concomitant agents. Preserve the full toxicity monitoring and stop instructions.

Also check: Gemcitabine: initial CKD guidance does not cancel a toxicity stop rule

Rxlist source

GlobalRPh RX List - Gemzar

Product / population
GEMZAR intravenous cytotoxic therapy; renal toxicity precautions distinct from stable-CKD dose selection.
Renal measure
Clinical renal assessment; no formal renal-impairment dosing study in selected label.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

Assess renal function before treatment and periodically. The source states that clinical studies in renal impairment were not conducted. Consider hemolytic uremic syndrome when renal deterioration accompanies hemolytic anemia, elevated bilirubin/LDH, reticulocytosis or thrombocytopenia. Permanently discontinue for HUS or severe renal impairment; renal failure may persist despite stopping treatment. This toxicity stop rule must not be replaced by an institution's initial dose advice for a patient with stable chronic kidney disease.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/gemzar-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - Gemzar

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

GEMZAR intravenous cytotoxic therapy; renal toxicity precautions distinct from stable-CKD dose selection.

Renal method: Clinical renal assessment; no formal renal-impairment dosing study in selected label.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Professional guidance

eviQ 333: advanced pancreatic cancer gemcitabine

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult locally advanced/metastatic pancreatic cancer single-agent protocol; not all gemcitabine combinations.

Renal method: Indexed eGFR (mL/min/1.73 m2); ADDIKD-based kidney guidance.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

indication and toxicity context

Gemcitabine: initial CKD guidance does not cancel a toxicity stop rule

eviQ supplies an initial indexed-eGFR approach for advanced pancreatic cancer. GEMZAR separately requires stopping for HUS or severe renal toxicity. These address different clinical states rather than permission to continue despite new injury.

How to use this: Establish baseline stability versus new drug-associated injury, indication and concomitant agents. Preserve the full toxicity monitoring and stop instructions.

GlobalRPh RX List - GemzareviQ 333: advanced pancreatic cancer gemcitabine

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - GemzareviQ 333: advanced pancreatic cancer gemcitabine
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/gemzar-drug/

Exact product and population

GEMZAR intravenous cytotoxic therapy; renal toxicity precautions distinct from stable-CKD dose selection.

RDM39-SCOPE-gemcitabine-gemzar · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Gemzar

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · GEMZAR intravenous cytotoxic therapy; renal toxicity precautions distinct from stable-CKD dose selection.

Renal method: Clinical renal assessment; no formal renal-impairment dosing study in selected label.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Assess renal function before treatment and periodically. The source states that clinical studies in renal impairment were not conducted. Consider hemolytic uremic syndrome when renal deterioration accompanies hemolytic anemia, elevated bilirubin/LDH, reticulocytosis or thrombocytopenia. Permanently discontinue for HUS or severe renal impairment; renal failure may persist despite stopping treatment. This toxicity stop rule must not be replaced by an institution's initial dose advice for a patient with stable chronic kidney disease.

RDM39-rxlist-gemcitabine-gemzar-c27f5e8acc-C1 · Source locator: Selected renal dosing, use in renal impairment, warnings and clinical pharmacology subsections; see named sections in summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/gemzar-drug/
Retrieved
2026-09-07
Renal-function method
Clinical renal assessment; no formal renal-impairment dosing study in selected label.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
2cc8b2f865ee08ea8dd41b1cce8140bb1f2108c234e896cda987b097909d3477
Separate professional-source layer

University and professional protocols

Professional

eviQ 333: advanced pancreatic cancer gemcitabine

Open original reference

Open / share this exact local source

eviQ / Cancer Institute NSW · Adult locally advanced/metastatic pancreatic cancer single-agent protocol; not all gemcitabine combinations.

Renal method: Indexed eGFR (mL/min/1.73 m2); ADDIKD-based kidney guidance.
Source date: Current retrieved protocol; kidney recommendations reference ADDIKD.
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

This protocol uses gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days, subject to its toxicity criteria. The kidney table retains full dose at eGFR >=60 and at 45-59, 30-44 and 15-29, with increased adverse-event risk flagged for the impaired bands. Below 15 without kidney replacement, or during replacement therapy, consult a multidisciplinary oncology/nephrology/clinical-pharmacology team. These initial CKD recommendations do not cancel a drug-induced HUS or severe-toxicity stop rule. Hematologic and other dose modifications remain separate.

RDM39-professional-gemcitabine-gemzar-3af575c24b-C1 · Source locator: Treatment schedule; Dose modifications > Kidney dosing recommendations

Source-specific limits

Kidney table and treatment schedule read in turn682275view1 and turn948264view4.

Source identity and provenance
Source family
professional_guidance
Source
https://www.eviq.org.au/medical-oncology/upper-gastrointestinal/pancreas-and-biliary/333-pancreas-advanced-gemcitabine
Retrieved
2026-09-07
Renal-function method
Indexed eGFR (mL/min/1.73 m2); ADDIKD-based kidney guidance.
Source date/version
Current retrieved protocol; kidney recommendations reference ADDIKD.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
4e77340ad2ab648735d4a3baa1665f01b9f34ebf5a431030a3f61473f758181c

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/gemzar-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
2648a49eb2c01db62f9ab37ac542e3f7e139e3712d0ceb907b394f5b716db928
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report